The expression of miR-490-3p and miR-503-5p in hepatocellular carcinoma tissues and their relationship with clinicopathological features and prognosis

Abstract

Abstract: Objective To investigate the expression of microRNA (miRNA)-490-3p and miR-503-5p in hepatocellular carcinoma (HCC) and their relationship with clinicopathological features and prognosis.Methods 102 HCC patients who underwent radical resection in Handan Central Hospital from March 2018 to March 2020 were selected. The expression of miR-490-3p and miR-503-5p in HCC tissues and adjacent tissues (more than 5 cm from the edge of cancer tissues) were detected by real-time fluorescence quantitative polymerase chain reaction. The expression of miR-490-3p and miR-503-5p in cancer tissues of HCC patients with different clinicopathological features was compared. The overall survival of HCC patients with different miR-490-3p and miR-503-5p expression were analyzed by Kaplan-Meier method. Log-Rank test was used to compare the differences in survival curves between different groups. Univariate and multivariate COX risk regression models were used to analyze the prognostic factors of HCC patients.Results The relative expression levels of miR-490-3p and miR-503-5p in HCC cancer tissues were (0.86±0.23) and (0.91±0.22) respectively, which were lower than those in cancer adjacent tissues (1.90±0.31) and (2.12±0.41), with a statistically significant difference (t=27.409, 26.379, P=0.000, 0.000). The expression of miR-490-3p and miR-503-5p in HCC tissues was related to the degree of tumor differentiation, the maximum diameter of tumor, and the Chinese liver cancer staging (CNLC), and the differences were statistically significant (all P<0.05). The expression of miR-490-3p and miR-503-5p was not related to gender, age, number of tumors, HBsAg and preoperative alpha-fetoprotein, and the difference was not statistically significant (all P>0.05). The 3-year overall survival rates of miR-490-3p high expression group and low expression group were 84.62% (44/52) and 48.00% (24/50) respectively. The 3-year overall survival rates of miR-503-5p high expression group and low expression group were 87.76% (43/49) and 50.94% (27/53) respectively. The 3-year cumulative survival rate of miR-490-3p low expression group and miR-503-5p low expression group was significantly lower than that of miR-490-3p high expression group and miR-503-5p high expression group respectively, and the difference was statistically significant (Log-rank χ²=16.231, 10.604, P=0.000, 0.001). CNLC stage IIIa, tumor maximum diameter ≥5 cm, and poor differentiation were independent risk factors affecting the prognosis of HCC patients, and increased expression of miR-490-3p and miR-503-5p was a protective factor.Conclusion The decrease expression of miR-490-3p and miR-503-5p in HCC patients is relate to poor clinicopathological features and is an independent risk factor affecting the prognosis of HCC patients.

Key words: Hepatocellular carcinoma, Microribonucleic acid-490-3p, Microribonucleic acid-503-5p, Pathological features, Prognosis

WANG Jun-wei, ZHANG Xiao-long, LI Yan, LIU Zheng, ZHANG Ji-guang, YUE Ya-ling. The expression of miR-490-3p and miR-503-5p in hepatocellular carcinoma tissues and their relationship with clinicopathological features and prognosis[J]. Chinese Hepatolgy, 2025, 30(3): 356-360.

References

[1] Toh M R, Wong E Y T, Wong S H, et al. Global epidemiology and genetics of hepatocellular carcinoma[J]. Gastroenterology,2023,164(5):766-782.
[2] Vogel A, Bathon M, Saborowski A. Advances in systemic therapy for the first-line treatment of unresectable HCC[J]. Expert Rev Anticancer Ther,2021,21(6):621-628.
[3] Ho P T B, Clark I M, Le L T T. MicroRNA-Based diagnosis and therapy[J]. Int J Mol Sci,2022,23(13):7167.
[4] Dai W, Dai J L, Tang M H, et al. lncRNA-SNHG15 accelerates the development of hepatocellular carcinoma by targeting miR-490-3p/ histone deacetylase 2 axis[J]. World J Gastroenterol,2019,25(38):5789-5799.
[5] Ju A, Shen Y, Yue A. Circ_0011232 contributes to hepatocellular carcinoma progression through miR-503-5p/AKT3 axis[J]. Hepatol Res,2022,52(6):532-545.
[6] Hu B, Ma X, Fu P, et al. The mRNA-miRNA-lncRNA regulatory network and factors associated with prognosis prediction of hepatocellular carcinoma[J]. Genomics Proteomics Bioinformatics,2021,19(6):913-925.
[7] 余灵祥, 肖朝辉, 纪旭, 等. 外泌体miRNA生物标志物在肝癌中的研究进展[J]. 现代生物医学进展,2019,19(1):171-174.
[8] Chen Y, Zhang R. Long non-coding RNA AL139002.1 promotes gastric cancer development by sponging microRNA-490-3p to regulate hepatitis A virus cellular receptor 1 expression[J]. Bioengineered,2021,12(1):1927-1938.
[9] Zheng K, Zhou X, Yu J, et al. Epigenetic silencing of miR-490-3p promotes development of an aggressive colorectal cancer phenotype through activation of the Wnt/β-catenin signaling pathway[J]. Cancer Lett,2016,376(1):178-187.
[10] Wang Y, Li Y, Li X. Ultrasound microbubble-mediated miR-503-5p downregulation suppressed in vitro CRC progression via promoting SALL1 expression[J]. Tissue Cell,2022,76(6):101811.
[11] Cai X, Nie J, Chen L, et al. Circ_0000267 promotes gastric cancer progression via sponging MiR-503-5p and regulating HMGA2 expression[J]. Mol Genet Genomic Med,2020,8(2):e1093.
[12] Jiang S P, Li Z R. MiR-503-5p regulates cell epithelial-to-mesenchymal transition, metastasis and prognosis of hepatocellular carcinoma through inhibiting WEE1[J]. Eur Rev Med Pharmacol Sci,2019,23(5):2028-2037.
[13] Li B, Liu L, Li X, et al. miR-503 suppresses metastasis of hepatocellular carcinoma cell by targeting PRMT1[J]. Biochem Biophys Res Commun,2015,464(4):982-987.

[1]	KANG Ya, MA Jin-xin. Predictive value of aMAP risk score combined with liver stiffness measurement for hepatocellular carcinoma associated with hepatitis B cirrhosis [J]. Chinese Hepatolgy, 2025, 30(3): 343-346.
[2]	ZHANG Ming-xing, ZHUANG Wen-qiong, SHI Li-min, CAI Si-qi. A network calculator based on the platelet index score effectively predicts the prognosis of patients with decompensated cirrhosis [J]. Chinese Hepatolgy, 2025, 30(2): 187-192.
[3]	WANG Qian, LIANG Shuang, LI Jing, XU Jia-qi, WANG Fang-xu. Application of contrast-enhanced ultrasound combined with serum alpha fetoprotein (AFP) and amyloid A/C-reactive protein (SAA/CRP) levels in the differential diagnosis of hepatocellular adenoma and carcinoma [J]. Chinese Hepatolgy, 2025, 30(2): 211-215.
[4]	LI Yun-hua, GAO Xin-yang. The value of combining the MRI manifestations of pumeixian liver bile stage donut nodules with DCE-MRI perfusion quantitative parameters in evaluating the efficacy of transcatheter arterial chemoembolization for hepatocellular carcinoma [J]. Chinese Hepatolgy, 2025, 30(2): 216-221.
[5]	XU Shan-shan, QIU Li-xia, LIU Ya-li, ZHANG Jing. The clinical features and prognosis of 360 patients with pathologically diagnosed drug-induced liver injury [J]. Chinese Hepatolgy, 2025, 30(1): 16-20.
[6]	XIANG Juan, QU Yan-Gang. Clinico-pathological characteristics of undifferentiated embryonal sarcoma in the liver [J]. Chinese Hepatolgy, 2025, 30(1): 46-49.
[7]	JIANG Cheng-cheng, DONG Xin-yuan. The value of cytokeratin-19, CA50, and alpha-fetoprotein in assessing disease progression in hepatocellular carcinoma [J]. Chinese Hepatolgy, 2025, 30(1): 50-54.
[8]	Sudbayan er Subuda, WU Xi-de, Udungova. Analysis of etiology, clinical features and prognosis of hepatic myelopathy [J]. Chinese Hepatolgy, 2025, 30(1): 74-77.
[9]	HU Zhi-liang, LI Feng-wei, WANG Kui. The establishment of a predictive model for the actual long-term survival after liver resection in hepatitis B-related intrahepatic cholangiocarcinoma [J]. Chinese Hepatolgy, 2024, 29(9): 1029-1034.
[10]	CHEN Yuan-li, ZENG De-feng, FAN Hui-wen. The value of contrast-enhanced ultrasound combined with ultrasound elastography in predicting microvascular invasion of hepatocellular carcinoma [J]. Chinese Hepatolgy, 2024, 29(9): 1035-1039.
[11]	ZHU Ji-lan, ZHAO Xia, WANG Shi-wei, YANG Lei. The predictive value of multiparametric magnetic resonance imaging combined with CT dynamic enhancement on the efficacy of immunotherapy for patients with advanced hepatocellular carcinoma [J]. Chinese Hepatolgy, 2024, 29(9): 1040-1046.
[12]	QIN Si-wei, ZHU Xiao-qiang, XU Lei-lei, LUO Xin. A comparison between TACE combined with sorafenib or ¹²⁵I seed implantation for the treatment of hepatocellular carcinoma patients with portal vein tumor thrombus and arteriovenous fistula [J]. Chinese Hepatolgy, 2024, 29(9): 1052-1055.
[13]	LIU Cui-cui, HE Yi, QIU Jing-qi, LIANG Shuang, WANG Qian, ZHANG Zhi-bo. The significance of contrast-enhanced ultrasound in assessing hepatocellular carcinoma in cirrhotic patients and its association with serum levels of AFP-L3, GPC3 and GP73 [J]. Chinese Hepatolgy, 2024, 29(9): 1056-1059.
[14]	YANG Zi-jun, YANG Jia-xin, GUO Li-li. The value of DCE-MRI combined with enhanced CT scan in evaluating the treatment effect of TACE on patients with primary hepatocellular carcinoma [J]. Chinese Hepatolgy, 2024, 29(9): 1060-1063.
[15]	WANG Guo-feng, JIA Yu-qing, SHU Chang-xin, CAI Xiao-dong, WANG Hong-bo, XU Jian-hong. A clinical comparison of open anatomical hepatectomy with different approaches for the treatment of hepatocellular carcinoma [J]. Chinese Hepatolgy, 2024, 29(9): 1064-1067.